News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Panacea Pharmaceuticals, Inc. Appoints Donald A. Zelm as Vice President for Finance (Business Wire)...``Panacea is in a position to effectively utilize Don`s financial management expertise as we continue our aggressive growth and approach the clinical trial phase for several of our drug candidates.`` About Panacea Pharmaceuticals Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system and cancer such as Alzheimer`s disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson`s disease....- Jan 18 12:01 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010118/md_panacea_2.html

Posted on: 01/18/2001

"Yahoo - Panacea Pharmaceuticals, Inc. Appoints Donald A. Zelm as Vice President for Finance"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
^DJI
^IXIC
^SPC
^IIX
^PSE
10576.21
2769.45
1339.04
319.68
907.33
-102.07
+0.96
-8.93
-0.02
-4.27
delayed 20 mins - disclaimer
Thursday January 18, 12:01 pm Eastern Time

Press Release

Panacea Pharmaceuticals, Inc. Appoints Donald A. Zelm as Vice President for Finance

ROCKVILLE, Md.--(BW HealthWire)--Jan. 18, 2001--Panacea Pharmaceuticals, Inc. announced today the appointment of Donald A. Zelm, M.B.A., C.P.A. as Vice President for Finance.

Mr. Zelm brings with him more than twenty years experience as a financial manager in the pharmaceutical industry.

"I am excited to join Panacea, with its promising programs, attractive product pipeline, and exceptional management and support team," stated Mr. Zelm.

Mr. Zelm spent the last eleven years with Sigma-Tau Pharmaceuticals, Inc. of Gaithersburg, Maryland. From 1989 to 1995, he served as Controller and from 1995 to 2000 as Vice President of Finance.

While serving in these capacities, he was responsible for the financial management of the company including accounting, budgeting, taxes, cash management, establishing internal controls, and evaluating new business opportunities. During Mr. Zelm's tenure, Sigma-Tau's annual revenue increased from $200 thousand to over $50 million.

He also participated in the negotiation of co-promotion agreements with Roche, SmithKline Beecham, Warner Lambert, and Abbott Laboratories, contracts for multi-center clinical trials, and large-scale contract manufacturing.

Prior to Sigma-Tau, Mr. Zelm served as Senior Financial Analyst for the Diagnostic Imaging Division of DuPont in Wilmington, Delaware, where he was responsible for coordinating and preparing the annual budget of a $500 million x-ray film and equipment division within the Medical Products Department. He was also responsible for the financial analysis of new product proposals and contracts.

Mr. Zelm served as Financial Planning Manager for American Critical Care, a division of American Hospital Supply Corporation and Baxter, where he was responsible for the annual budgets and monthly forecasts of the Critical Care Division, a $65 million pharmaceutical business with over 400 employees.

Mr. Zelm also spent several years with Arthur Andersen & Company as a Senior Auditor.

Mr. Zelm received his B.S. in Accountancy from the University of Illinois and his M.B.A. from DePaul University in Chicago, Illinois.

"Don's highly relevant industry specific experience is welcomed given the tremendous partnering opportunities and financing possibilities available to the Company," stated Kasra Ghanbari, Chief Operating Officer of the Company. "Panacea is in a position to effectively utilize Don's financial management expertise as we continue our aggressive growth and approach the clinical trial phase for several of our drug candidates."

About Panacea Pharmaceuticals

Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system and cancer such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson's disease.

Changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation are utilized to develop diagnostic tests and therapeutic agents.

More information is available at www.PanaceaPharma.com, a web site developed by eiCommunications.com, Inc. (www.eiCommunications.com), which offers written communications and web site promotion solutions for the Information Age.


Contact:
     Panacea Pharmaceuticals, Inc.
     Kasra Ghanbari, 240/453-6295

Email this story - Most-emailed articles - Most-viewed articles


Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service

Copyright 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740